BACKGROUND: @entity955 ( @entity955 ) is the most common @entity943 seen in cardiovascular departments. Treatments include medical interventions and @entity1212 . Due to uncertainties in medical therapies for @entity955 , and the need to continue sinus rhythm, ablation has been recently considered as a viable alternative. Many new ablation methods based on pulmonary vein isolation (PVI) have been developed. OBJECTIVES: The primary objective of this review was to assess the beneficial and harmful effects of @entity1212 ( @entity1212 ) in comparison with medical treatment in @entity1 with paroxysmal and persistent @entity955 . The secondary objective was to determine the best regimen of @entity1212 . SEARCH METHODS: Searches were run on The Cochrane Central Register of Controlled Trials (CENTRAL) on The Cochrane Library Issue 3 2009, MEDLINE (1950 to August 2009), EMBASE (1980 to August 2009), the Chinese Biomedical Literature Database (1978 to August 2009) and the CKNI Chinese Paper Database (1994 to 2009) . Several journals published in Chinese were also handsearched. SELECTION CRITERIA: @entity23 ( @entity23 ) in @entity1 with paroxysmal and persistent @entity955 treated by any type of @entity1212 method. Two reviewers independently selected the trials for inclusion. DATA COLLECTION AND ANALYSIS: Assessments of risk of bias were performed by two reviewers, and relative risk (RR) and 95% confidence intervals (CI) were used for dichotomous variables. Meta-analysis were performed where appropriate. MAIN RESULTS: A total of 32 @entity23 (3,560 @entity1 ) were included. @entity23 were small in size and of poor quality. @entity1212 compared with medical therapies: seven @entity23 indicated that @entity1212 had a better effect in inhibiting recurrence of @entity955 [RR 0.27; 95% CI 0.18, 0.41)] but there was significant heterogeneity. There was limited evidence to suggest that sinus rhythm was restored during @entity1212 (one small trial: RR 0.28, 95% CI 0.20-0.40), and at the end of follow-up (RR 1.87, 95% CI 1.31-2.67; I(2)=83%). There were no differences in mortality (RR, 0.50, 95% CI 0.04 to 5.65), fatal and @entity887 (RR 1.01, 95% CI 0.18 to 5.68) or death from thrombo-embolic events (RR 3.04, 95% CI 0.13 to 73.43).Comparisons of different CAs; 25 @entity23 compared @entity1212 of various kinds. Circumferential @entity358 was better than segmental @entity358 in improving symptoms of @entity955 (p<=0.01) and in reducing the recurrence of @entity955 (p<0.01). There is limited evidence to suggest which ablation method was the best. AUTHORS' CONCLUSIONS: There is limited evidence to suggest that @entity1212 may be a better treatment option compared to medical therapies in the management of persistent @entity955 . This review was also unable to recommend the best @entity1212 method.

Catheter ablation for paroxysmal and persistent XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'people'] @entity1212 :: ('MESH:D055499', 'Disease') :: ['catheter ablation', 'CA'] @entity23 :: ('MESH:D007174', 'Disease') :: ['Randomised controlled trials', 'RCTs'] @entity887 :: ('MESH:D004617', 'Disease') :: ['non-fatal embolic complication'] @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary vein ablation'] @entity955 :: ('MESH:D001281', 'Disease') :: ['Atrial fibrillation', 'AF'] @entity943 :: ('MESH:D001145', 'Disease') :: ['cardiac arrhythmia']
@entity955 :: (MESH:D001281,Disease) :: ['atrial fibrillation']
